Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0165 -0.0006 (-3.51%)
Streaming Delayed Price Updated: 1:57 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aspire Biopharma Holdings, Inc. - Warrant

< Previous 1 2 Next >
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Via ACCESS Newswire
News headline image
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion
Via ACCESS Newswire
News headline image
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director
Via ACCESS Newswire
News headline image
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026
Via ACCESS Newswire
News headline image
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack
Via ACCESS Newswire
News headline image
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
Via ACCESS Newswire
News headline image
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Via ACCESS Newswire
News headline image
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Reverse Stock Split
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
Via ACCESS Newswire
News headline image
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
Via ACCESS Newswire
News headline image
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Provides Q3 2025 Business Update
Via ACCESS Newswire
News headline image
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Via ACCESS Newswire
News headline image
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
Via ACCESS Newswire
News headline image
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
Via ACCESS Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.